"A Process Of Preparing Alcaftadine"

Enaltec Labs Private Limited
Granted App No 3449/MUM/2012 Patent 308482 Chemical

Patent information

IP India · live record
Application number
3449/MUM/2012
Filing date
06 December 2012
Status
Granted
Legal status
Inforce
Publication number
27/2014
Publication type
INA
Invention field
Chemical
Patent number
308482
Grant date
04 March 2019
Next renewal due
06 December 2026

Abstract

The present invention relates to a process of preparing alcaftadine compound of structural formula I by employing pure compound of structural formula VIII.

Applicants

1
India
ENALTEC LABS PRIVATE LIMITED 17TH FLOOR, KESAR SOLITAIRE, PLOT NO.5 SECTOR-19, SANPADA, NAVI MUMBAI MAHARASHTRA, INDIA. PIN CODE: 400705

Inventors

5
India
BOBBA VENKATA SIVAKUMARENALTEC LABS PRIVATE LIMITED. PLOT NO.W-59 A, ADDL MIDC, AMBERNATH, DIST-THANE 421506, MAHARASHTRA, INDIA.
India
KODALI ESWARA RAOENALTEC LABS PRIVATE LIMITED. PLOT NO.W-59 A, ADDL. MIDC, AMBERNATH, DIST-THANE 421506, MAHARASHTRA, INDIA.
India
GIRISH BANSILAL PATELENALTEC LABS PRIVATE LIMITED. PLOT NO.W-59 A, ADDL. MIDC, AMBERNATH, DIST-THANE 421506, MAHARASHTRA, INDIA.
India
SANJAY DASHRATH VAIDYAENALTEC LABS PRIVATE LIMITED. PLOT NO.W-59 A, ADDL. MIDC, AMBERNATH, DIST-THANE 421506, MAHARASHTRA, INDIA.
India
ALOK PRAMOD TRIPATHIENALTEC LABS PRIVATE LIMITED. PLOT NO.W-59 A, ADDL. MIDC, AMBERNATH, DIST-THANE 421506, MAHARASHTRA, INDIA.

Claims

10
1 A process for purification of compound of structural formula VIII comprising the steps of: a. dissolving crude compound of structural formula VIII in an ether solvent and, b. isolating substantially pure compound of structural formula VIII.
2 The process according to Claim 1, wherein crude compound of structural formula VIII was dissolved at a temperature in the range of 40°C to 80°C maintained for 30 minutes to 2 hours and then cooled to 20°C to 30°C to get substantially pure compound of structural formula VIII.
3 The process according to Claim 1, wherein ether solvent is selected from the group consisting of tetrahydrofuran, 1, 4-dioxane, diethyl ether, diisopropyl ether, dibutyl ether, methyl tertiary butyl ether, methyl ethyl ether, methyl isobutyl ether or mixture(s) thereof.
4 The process according to Claim 1, wherein the substantially pure compound of structural formula VIII is isolated by the steps of filtration, centrifugation, washing, drying or combinations thereof.
5 The process according to Claim 4, wherein the isolated substantially pure compound of structural formula VIII is dried at a temperature in the range of 40°C to 80°C for a period of 2 hours to 12 hours under reduced pressure.
6 A substantially pure compound of structural formula VIII, having less than 15% of compound of structural formula XIV.
7 A process of preparing alcaftadine compound of structural formula I comprising the steps of: a. dissolving crude compound of structural formula VIII in an ether solvent and, b. isolating substantially pure compound of structural formula VIII and c. converting substantially pure compound of structural formula VIII in to alcaftadine compound of structural formula I.
8 The process according to Claim 7, wherein crude compound of structural formula VIII was dissolved at a temperature in the range of 40°C to 80°C maintained for 30 minutes to 2 hours and then cooled to 20°C to 30°C to get substantially pure compound of structural formula VIII.
9 The process according to Claim 7, wherein ether solvent is selected from the group consisting of tetrahydrofuran, 1, 4-dioxane, diethyl ether, diisopropyl ether, dibutyl ether, methyl tertiary butyl ether, methyl ethyl ether, methyl isobutyl ether or mixture(s) thereof.
10 The process according to Claim 7, wherein the substantially pure compound of structural formula VIII is isolated by the steps of filtration, centrifugation, washing, drying or combinations thereof.

Specification

Show full textCollapse

FORM 2 THE PATENT ACT, 1970 (39 of 1970) & The Patents Rules, 2003 COMPLETE SPECIFICATION (See section 10 and rule 13) Title of the invention "A PROCESS OF PREPARING ALCAFTADINE" Enaltec Labs Pvt. Ltd. an Indian Company, having its Registered Office at 17thFloor, Kesar Solitaire, Plot No.5 Sector-19, Sanpada, Navi Mumbai Maharashtra. India. Pin Code: 400705 1, The following specification particularly describes the invention and the manner in which it is to be performed.

A PROCESS OF PREPARING ALCAFTADINE FIELD OF THE INVENTION: The present invention relates to a process of preparing alcaftadine compound of structural formula 1 by employing pure compound of structural formula VIII.

BACKGROUND OF THE INVENTION: Alcaftadine is chemically 6, ll-dihydro-ll-(l-methyl-4-piperidinylidene)-5H-irnidazo [2, 1-b] [3] benzazepine-3-carboxaldehyde and is known from U.S Patent No. 5,468,743 and is represented by a compound of structural formula I.

Alcaftadine is a H1 histamine receptor antagonist sold in USA under the proprietary name of "LASTACAFT" and is indicated for the prevention of itching associated with allergic conjunctivitis. U.S Patent No. 5,468,743 describes analogous processes of preparing alcaftadine compound of structural formula I as shown below in scheme no. I, scheme no. II and scheme no. III.

The processes of preparing compound of structural formula VIII according to the above mentioned references produce more than 25% of compound of structural formula XIV.

The compound of structural formula XIV is being carry-forwarded into the further steps of reactions of preparing alcaftadine compound of structural formula I and therefore there is a need in the art to develop an improved process of preparing compound of structural formula VIII, which obviates the prior-art problems.

SUMMARY OF THE INVENTION: First aspect of the present invention is to provide a substantially pure compound of structural formula VIII.

According to another aspect, the present invention relates to process for the purification of compound of structural formula VIII. According to another aspect, the present invention relates to a process for purification of compound of structural formula VIII comprising the steps of: a. dissolving crude compound of structural formula VIII in an ether solvent and, b. isolating substantially pure compound of structural formula VIII. According to another aspect, the present invention relates to a process of preparing alcaftadine compound of structural formula I comprising the steps of: a. dissolving crude compound of structural formula VIII in an ether solvent, b. isolating substantially pure compound of structural formula VIII and c. converting substantially pure compound of structural formula VIII into alcaftadine compound of structural formula I. According to another aspect, the present invention relates to solvated compound of structural formula XV.

According to another aspect, the present invention relates to tetrahydrofuran solvated compound of structural formula XVI.

According to another aspect, the present invention relates to a crystalline compound of structural formula VIII. BRIEF DESCRIPTION OF THE DRAWINGS: Figure I depicts X-ray diffraction pattern of crystalline compound of structural formula VIII. Figure 2 depicts Infra-Red spectra of crystalline compound of structural formula VIII. DETAIL DESCRIPTION OF THE INVENTION: In an embodiment the present invention relates to a process for the preparation of substantially pure compound of structural formula VIII.

The term "substantially pure compound of structural formula VIII" described herein referred to compound of structural formula VIII having less than 15% of compound of structural formula XIV.

In another embodiment, the present invention relates to a process for purification of compound of structural formula VIII comprising the steps of: a. dissolving crude compound of structural formula VIII in an ether solvent and, b. isolating substantially pure compound of structural formula VIII. The crude compound of structural formula VIII used according to the present invention can be prepared by methods disclosed in the art such as those described in U.S Patent No. 5,468,743, which is incorporated herein by reference. The purification of compound of structural formula VIII is carried out by dissolving crude compound of structural formula VIII in an ether solvent at a temperature in the range of 40oC to 80°C and maintained for 30 minutes to 2 hours. The resulting solution was cooled to 20oC to 30°C to get substantially pure compound of structural formula VIII.

Ether solvents can be selected from the group comprising, but not limited to, tetrahydrofuran, 1, 4-dioxane, diethyl ether, diisopropyl ether, dibutyl ether, methyl tertiary butyl ether, methyl ethyl ether, methyl isobutyl ether or mixture(s) thereof. The substantially pure compound of structural formula VIII may be isolated by any known process in the art such as filtration, centrifugation, washing, drying or the combinations thereof. The isolated substantially pure compound of structural formula VIII may be dried at a temperature in the range of 40°C to 80°C for a period of 2 hours to 12 hours under reduced pressure. The solvates of compound of structural formula XV can be selected from the group comprising, but not limited to, tetrahydrofuran solvate, 1, 4-dioxane solvate, diethyl ether solvate, diisopropyl ether solvate, dibutyl ether solvate, methyl tertiary butyl ether solvate, methyl ethyl ether solvate or methyl isobutyl ether solvate. The example of solvated compound of structural formula XV may include tetrahydrofuran solvated compound of structural formula XVI.

The isolated substantially pure compound of structural formula VIII may be crystalline or amorphous in nature. In another embodiment, the present invention relates to a crystalline compound of structural formula VIII characterized by X-ray diffraction pattern having peaks at 8.0, 11.0, 12.8, 14.0,

15.0, 15.7, 16.9, 18.7, 19.3, 20.3, 20.6, 21.8, 22.2, 22.6, 25.2, 25.8, 27.1, 27.8, 28.8, 30.7 ± 0.2 degrees two theta. In another embodiment the present invention relates to a crystalline compound of structural formula VIII characterized by X-ray diffraction pattern as depicted in Figure 1. In another embodiment the present invention relates to a crystalline compound of structural formula VIII characterized by Infra-Red spectrum as depicted in Figure 2. The pure compound of structural formula VIII may be converted into alcaftadine compound of structural formula I by methods known in the art such as those described in U.S Patent No. 5,468,743, which are incorporated herein by reference only. EXAMPLES: In the following examples, the preferred embodiments of the present invention are described only by way of illustrating the process of the invention. However, these are not intended to limit the scope of the present invention in any way. Example 1: Purification of compound of structural formula VIII A crude compound of structural formula VIII (50gm) was dissolved in tetrahydrofuran (500ml) at 60-65°C and maintained for 1 hour. The resulting solution was cooled to 25-35°C to get solid. The resulting solids were filtered, washed with tetrahydrofuran (50ml) and dried at 45-55°C under reduced pressure for 8 hours to get pure compound of structural formula VIII. Yield: 35gm Purity: 99.9% (By HPLC) Example 2: Purification of compound of structural formula VIII A crude compound of structural formula VIII (l0gm) was dissolved in tetrahydrofuran (100ml) at 60-65°C and maintained for 1 hour. The resulting solution was cooled to 25-35°C to get solid.

The resulting solids were filtered, washed with tetrahydrofuran (10ml) and dried at 45-55°C under reduced pressure for 5 hours to get pure compound of structural formula VIII. Yield: 8.5gm Purity: 99.9% (By HPLC) Example 3: Purification of compound of structural formula VIII A crude compound of structural formula VIII (lOgm) was dissolved in 1, 4-dioxane (100ml) at 60-65°C and maintained for 1 hour. The resulting solution was cooled to 25-35°C to get solid. The resulting solids were filtered, washed with 1, 4-dioxane (20ml) and dried at 45-55°C under reduced pressure for 6 hours to get pure compound of structural formula VIII. Yield: 8.7gm Purity: 99.8% (By HPLC)

WE CLAIM: 1. A process for purification of compound of structural formula VIII comprising the steps of: a. dissolving crude compound of structural formula VIII in an ether solvent and, b. isolating substantially pure compound of structural formula VIII.

2. The process according to Claim 1, wherein crude compound of structural formula VIII was dissolved at a temperature in the range of 40°C to 80°C maintained for 30 minutes to 2 hours and then cooled to 20°C to 30°C to get substantially pure compound of structural formula VIII. 3. The process according to Claim 1, wherein ether solvent is selected from the group consisting of tetrahydrofuran, 1, 4-dioxane, diethyl ether, diisopropyl ether, dibutyl ether, methyl tertiary butyl ether, methyl ethyl ether, methyl isobutyl ether or mixture(s) thereof. 4. The process according to Claim 1, wherein the substantially pure compound of structural formula VIII is isolated by the steps of filtration, centrifugation, washing, drying or combinations thereof. 5. The process according to Claim 4, wherein the isolated substantially pure compound of structural formula VIII is dried at a temperature in the range of 40°C to 80°C for a period of 2 hours to 12 hours under reduced pressure. 6. A substantially pure compound of structural formula VIII, having less than 15% of compound of structural formula XIV.

7. A process of preparing alcaftadine compound of structural formula I comprising the steps of: a. dissolving crude compound of structural formula VIII in an ether solvent and, b. isolating substantially pure compound of structural formula VIII and c. converting substantially pure compound of structural formula VIII in to alcaftadine compound of structural formula I. 8. The process according to Claim 7, wherein crude compound of structural formula VIII was dissolved at a temperature in the range of 40°C to 80°C maintained for 30 minutes to 2 hours and then cooled to 20°C to 30°C to get substantially pure compound of structural formula VIII. 9. The process according to Claim 7, wherein ether solvent is selected from the group consisting of tetrahydrofuran, 1, 4-dioxane, diethyl ether, diisopropyl ether, dibutyl ether, methyl tertiary butyl ether, methyl ethyl ether, methyl isobutyl ether or mixture(s) thereof. 10. The process according to Claim 7, wherein the substantially pure compound of structural formula VIII is isolated by the steps of filtration, centrifugation, washing, drying or combinations thereof.

Documents

Sign in to open
Orders
Section
Application documents
1 3449-MUM-2012-FORM 5(25-11-2013).pdf 25 Nov 2013
2 3449-MUM-2012-FORM 2(TITLE PAGE)-(25-11-2013).pdf 25 Nov 2013
3 3449-MUM-2012-FORM 2(25-11-2013).pdf 25 Nov 2013
4 3449-MUM-2012-DRAWING(25-11-2013).pdf 25 Nov 2013
5 3449-MUM-2012-DESCRIPTION(COMPLETE)-(25-11-2013).pdf 25 Nov 2013
6 3449-MUM-2012-CORRESPONDENCE(25-11-2013).pdf 25 Nov 2013
7 3449-MUM-2012-CLAIMS(25-11-2013).pdf 25 Nov 2013
8 3449-MUM-2012-ABSTRACT(25-11-2013).pdf 25 Nov 2013
9 3449-MUM-2012-OTHER DOCUMENT-27-03-2017.pdf 27 Mar 2017
10 3449-MUM-2012-FORM 3-27-03-2017.pdf 27 Mar 2017
11 3449-MUM-2012-CORRESPONDENCE-27-03-2017.pdf 27 Mar 2017
12 ABSTRACT 1.jpg 11 Aug 2018
13 3449-MUM-2012-PCT Search Report-030815.pdf 11 Aug 2018
14 3449-MUM-2012-OTHERS-211016.pdf 11 Aug 2018
15 3449-MUM-2012-OTHERS-030516.pdf 11 Aug 2018
16 3449-MUM-2012-OTHERS (Marked Copy)-200718.pdf 11 Aug 2018
17 3449-MUM-2012-Other PCT Form-030815.pdf 11 Aug 2018
18 3449-MUM-2012-Other Patent Document-030815.pdf 11 Aug 2018
19 3449-MUM-2012-Other - US PATENT DOCUMENTS-200718.pdf 11 Aug 2018
20 3449-MUM-2012-FORM 3.pdf 11 Aug 2018
21 3449-MUM-2012-Form 3-211016.pdf 11 Aug 2018
22 3449-MUM-2012-Form 3-200718.pdf 11 Aug 2018
23 3449-MUM-2012-Form 3-030815.pdf 11 Aug 2018
24 3449-MUM-2012-Form 3-030516.pdf 11 Aug 2018
25 3449-MUM-2012-FORM 2.pdf 11 Aug 2018
26 3449-MUM-2012-FORM 2(TITLE PAGE).pdf 11 Aug 2018
27 3449-MUM-2012-Form 2(Title Page)-200718.pdf 11 Aug 2018
28 3449-MUM-2012-Form 18-030815.pdf 11 Aug 2018
29 3449-MUM-2012-FORM 1.pdf 11 Aug 2018
30 3449-MUM-2012-FER.pdf 11 Aug 2018
31 3449-MUM-2012-Examination Report Reply Recieved-200718.pdf 11 Aug 2018
32 3449-MUM-2012-DRAWING.pdf 11 Aug 2018
33 3449-MUM-2012-Drawing-200718.pdf 11 Aug 2018
34 3449-MUM-2012-DESCRIPTION(PROVISIONAL).pdf 11 Aug 2018
35 3449-MUM-2012-CORRESPONDENCE.pdf 11 Aug 2018
36 3449-MUM-2012-Correspondence-211016.pdf 11 Aug 2018
37 3449-MUM-2012-Correspondence-030815.pdf 11 Aug 2018
38 3449-MUM-2012-Correspondence-030516.pdf 11 Aug 2018
39 3449-MUM-2012-Claims-200718.pdf 11 Aug 2018
40 3449-MUM-2012-Amended Pages Of Specification-200718.pdf 11 Aug 2018
41 3449-MUM-2012-Abstract-200718.pdf 11 Aug 2018
42 3449-MUM-2012-HearingNoticeLetter.pdf 05 Dec 2018
43 3449-MUM-2012-Reply to Hearing-300119.pdf 02 Feb 2019
44 3449-MUM-2012-Power of Attorney-300119.pdf 02 Feb 2019
45 3449-MUM-2012-Petition Under Rule 137-300119.pdf 02 Feb 2019
46 3449-MUM-2012-Marked Copy-300119.pdf 02 Feb 2019
47 3449-MUM-2012-Form 2(Title Page)-300119.pdf 02 Feb 2019
48 3449-MUM-2012-Drawing-300119.pdf 02 Feb 2019
49 3449-MUM-2012-Claims-300119.pdf 02 Feb 2019
50 3449-MUM-2012-Amended Pages Of Specification-300119.pdf 02 Feb 2019
51 3449-MUM-2012-Abstract-300119.pdf 02 Feb 2019
52 3449-MUM-2012-REPLY TO HEARING-200219.pdf 21 Feb 2019
53 3449-MUM-2012-Marked Copy-200219.pdf 21 Feb 2019
54 3449-MUM-2012-Form 2(Title Page)-200219.pdf 21 Feb 2019
55 3449-MUM-2012-Drawing-200219.pdf 21 Feb 2019
56 3449-MUM-2012-Claims-200219.pdf 21 Feb 2019
57 3449-MUM-2012-Amended Pages Of Specification-200219.pdf 21 Feb 2019
58 3449-MUM-2012-Abstract-200219.pdf 21 Feb 2019
59 3449-MUM-2012-REPLY TO HEARING-260219.pdf 01 Mar 2019
60 3449-MUM-2012-Marked Copy-260219.pdf 01 Mar 2019
61 3449-MUM-2012-Form 2(Title Page)-260219.pdf 01 Mar 2019
62 3449-MUM-2012-Form 1-260219.pdf 01 Mar 2019
63 3449-MUM-2012-Drawing-260219.pdf 01 Mar 2019
64 3449-MUM-2012-Claims-260219.pdf 01 Mar 2019
65 3449-MUM-2012-Amended Pages Of Specification-260219.pdf 01 Mar 2019
66 3449-MUM-2012-Abstract-260219.pdf 01 Mar 2019
67 3449-MUM-2012-PatentCertificate04-03-2019.pdf 04 Mar 2019
68 3449-MUM-2012-IntimationOfGrant04-03-2019.pdf 04 Mar 2019
69 308482-Correspndence (Renewal)-260419.pdf 30 Apr 2019
70 308482-CORRESPONDANCE(RENEWAL)-141221.pdf 16 Dec 2021
71 308482-Form 4-151222.pdf 20 Dec 2022
72 308482-Correspondence-151222.pdf 20 Dec 2022
73 308482-Correspondence (Renewal)-151222.pdf 20 Dec 2022
74 308482-FORM 4-060524.pdf 11 May 2024
75 308482-CORRESPONDENCE-060524.pdf 11 May 2024
76 308482-CORRESPONDENCE RENEWAL-060524.pdf 11 May 2024
77 308482-FORM 4-300425.pdf 13 May 2025
78 308482-CORRESPONDENCE RENEWAL-300425.pdf 13 May 2025
79 308482-CORRESPONDENCE RENEWAL-041225.pdf 05 Dec 2025
80 308482-FORM 27-230926.pdf 29 Sep 2026
Search strategy
1SearchStrategyof3449-MUM-2012_04-04-2018.pdf

ERegister / renewals

Inforce
3rd Renewed 26 Apr 2019 Period 06 Dec 2014 – 06 Dec 2015 · CBR 9721 · Certificate 7061 ₹4,400
4th Renewed 26 Apr 2019 Period 06 Dec 2015 – 06 Dec 2016 · CBR 9721 · Certificate 7061 ₹4,400
5th Renewed 26 Apr 2019 Period 06 Dec 2016 – 06 Dec 2017 · CBR 9721 · Certificate 7061 ₹4,400
6th Renewed 26 Apr 2019 Period 06 Dec 2017 – 06 Dec 2018 · CBR 9721 · Certificate 7061 ₹4,400
7th Renewed 26 Apr 2019 Period 06 Dec 2018 – 06 Dec 2019 · CBR 9721 · Certificate 7061 ₹13,200
8th Renewed 26 Apr 2019 Period 06 Dec 2019 – 06 Dec 2020 · CBR 9721 · Certificate 7061 ₹13,200
9th Renewed 26 Apr 2019 Period 06 Dec 2020 – 06 Dec 2021 · CBR 9721 · Certificate 7061 ₹13,200
10th Renewed 14 Dec 2021 Period 06 Dec 2021 – 06 Dec 2022 · CBR 29353 · Certificate 33743 ₹13,200
11th Renewed 15 Dec 2022 Period 06 Dec 2022 – 06 Dec 2023 · CBR 33041 · Certificate 35886 ₹26,400
12th Renewed 06 May 2024 Period 06 Dec 2023 – 06 Dec 2024 · CBR 21830 · Certificate 53128 ₹26,400
13th Renewed 30 Apr 2025 Period 06 Dec 2024 – 06 Dec 2025 · CBR 16606 · Certificate 18793 ₹26,400
14th Renewed 04 Dec 2025 Period 06 Dec 2025 – 06 Dec 2026 · CBR 48987 · Certificate 45182 ₹26,400